Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone914-347-4300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$471.43 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable
Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions
What is Acorda Therapeutics' stock symbol?
Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."
How were Acorda Therapeutics' earnings last quarter?
Acorda Therapeutics Inc (NASDAQ:ACOR) announced its quarterly earnings data on Thursday, February, 14th. The biopharmaceutical company reported $0.45 earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.19) by $1.64. The biopharmaceutical company had revenue of $69.20 million for the quarter, compared to analysts' expectations of $48.12 million. Acorda Therapeutics had a return on equity of 12.98% and a net margin of 7.14%. Acorda Therapeutics's revenue for the quarter was down 63.3% compared to the same quarter last year. During the same period last year, the firm posted $0.61 EPS. View Acorda Therapeutics' Earnings History.
When is Acorda Therapeutics' next earnings date?
What price target have analysts set for ACOR?
9 analysts have issued 12 month price targets for Acorda Therapeutics' stock. Their predictions range from $10.00 to $33.00. On average, they expect Acorda Therapeutics' share price to reach $21.25 in the next year. This suggests a possible upside of 59.9% from the stock's current price. View Analyst Price Targets for Acorda Therapeutics.
What is the consensus analysts' recommendation for Acorda Therapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acorda Therapeutics in the last year. There are currently 2 sell ratings, 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Acorda Therapeutics.
What are Wall Street analysts saying about Acorda Therapeutics stock?
Here are some recent quotes from research analysts about Acorda Therapeutics stock:
- 1. According to Zacks Investment Research, "Acorda beat estimates for earnings as well as revenues in Q4. The company got a huge boost with the approval of Inbrija in the United States slightly before the scheduled time period. Inbrija is also under review in the EU with a decision expected soon. The company is working on strengthening its Parkinson’s portfolio by focusing on Inbrija. Acorda boasts a strong pipeline addressing a wide range of disorders. The restructuring initiative is also saving costs. However, its key multiple sclerosis drug Ampyra is facing a generic competition which is significantly hurting Acorda’s top-line. The company expects to see a peristent decline in Ampyra sales during the quarters ahead in 2019. Shares of Acorda have underperformed the industry in the year so far." (3/18/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating but raise our price target on ACOR to $20 from $19. On Thursday, Acorda reported 4Q18 financials and detailed future commercialization plans for Inbrija, including monthly WAC pricing of $950, ~25% higher than our projections. The company reported net Ampyra revenues of $64.2M, higher than consensus $46.8M, reflecting a steep decline from the prior quarter, but clearly not as bad as some expected (we were $75.8M). That said, we anticipate Amp revs to continue to decline and therefore do not include Amp sales in our valuation of ACOR shares. Going forward, we see Acorda’s fate being clearly in the hands of Inbrija for the next phase of growth." (2/15/2019)
- 3. JPMorgan Chase & Co. analysts commented, "Friday, HSGX disclosed that discussions with the FDA had informally concluded ultimately resulting in the suspension of NeoCart’s development. The FDA notified HSGX that the company would be required to run an additional clinical trial to submit the BLA for NeoCart. Given HSGX’s capital position, this is not feasible and HSGX decided to suspend NeoCart development. To that end, HSGX will now explore all strategic options. HSGX’s outcome creates a few takeaways, in our view, regarding the cartilage segment which we discuss below." (12/26/2018)
- 4. HC Wainwright analysts commented, "Valuation methodology, risks, and uncertainties. We currently ascribe $570M to AMPYRA and $850M to INBRIJA on a risk-adjusted net present value (rNPV) basis, using an 85% probability of success and a 15% discount rate for INBRIJA along with a 12% discount rate for AMPYRA." (11/5/2018)
- 5. Jefferies Financial Group Inc analysts commented, "Q3 beat due to delayed launch of generic Amprya last qtr…however, IMS points to -40% Q3 reduction in TRx already and as expected. Key milestone for ACOR is potential approval of 5th PDUFA. Analysis below suggests probability of approval is incrementally higher given recent developments – but we are Hold due to fairly balanced risk/reward up and down on the scenarios. With Ampyra generic happening now as expected, focus shifts to approval of Inbrija and whether ACOR should remain a standalone or look to sell itself to maximize value. When asked on the call, mgmt. says they are regularly exploring all options to maximize shareholder value (though if they do an OUS partnership as guided we predict stock would go down based on less M&A likelihood)." (11/4/2018)
Has Acorda Therapeutics been receiving favorable news coverage?
News headlines about ACOR stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Acorda Therapeutics earned a news impact score of -1.4 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future.
Who are some of Acorda Therapeutics' key competitors?
Some companies that are related to Acorda Therapeutics include Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Rubius Therapeutics (RUBY), Momenta Pharmaceuticals (MNTA), Alector (ALEC), Iovance Biotherapeutics (IOVA), Editas Medicine (EDIT) and Fate Therapeutics (FATE).
What other stocks do shareholders of Acorda Therapeutics own?
Who are Acorda Therapeutics' key executives?
Acorda Therapeutics' management team includes the folowing people:
- Dr. Ron Cohen, Founder, CEO, Pres & Director (Age 63)
- Mr. David Lawrence, Chief Technology officer, Chief of Bus. Operations & Principal Accounting Officer (Age 61)
- Ms. Lauren M. Sabella, Chief Commercial Officer (Age 58)
- Mr. Andrew Asa Hindman, Chief Bus. Officer (Age 46)
- Dr. Burkhard Blank, Chief Medical Officer (Age 64)
Who are Acorda Therapeutics' major shareholders?
Acorda Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (6.10%), Northern Trust Corp (2.11%), Norges Bank (1.98%), Millennium Management LLC (1.61%), Acadian Asset Management LLC (1.23%) and Prudential Financial Inc. (1.23%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Barry E Greene, Burkhard Blank, David Lawrence, Ian F Smith, Lauren M Sabella, Lorin Randall, Ron Cohen, Scopia Capital Management Lp and Steven M Rauscher. View Institutional Ownership Trends for Acorda Therapeutics.
Which major investors are selling Acorda Therapeutics stock?
ACOR stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC, James Investment Research Inc., State Board of Administration of Florida Retirement System, Squarepoint Ops LLC, Geode Capital Management LLC, Geode Capital Management LLC, MetLife Investment Advisors LLC and Northern Trust Corp. Company insiders that have sold Acorda Therapeutics company stock in the last year include Andrew A Hindman, Burkhard Blank, David Lawrence, Ian F Smith, Lauren M Sabella, Lorin Randall, Ron Cohen, Scopia Capital Management Lp and Steven M Rauscher. View Insider Buying and Selling for Acorda Therapeutics.
Which major investors are buying Acorda Therapeutics stock?
ACOR stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Two Sigma Investments LP, Prudential Financial Inc., Acadian Asset Management LLC, Robeco Institutional Asset Management B.V., Connor Clark & Lunn Investment Management Ltd., Ontario Teachers Pension Plan Board and Bowling Portfolio Management LLC. Company insiders that have bought Acorda Therapeutics stock in the last two years include Ron Cohen and Scopia Capital Management Lp. View Insider Buying and Selling for Acorda Therapeutics.
How do I buy shares of Acorda Therapeutics?
Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acorda Therapeutics' stock price today?
One share of ACOR stock can currently be purchased for approximately $13.29.
How big of a company is Acorda Therapeutics?
Acorda Therapeutics has a market capitalization of $633.04 million and generates $471.43 million in revenue each year. The biopharmaceutical company earns $33.68 million in net income (profit) each year or $1.82 on an earnings per share basis.
What is Acorda Therapeutics' official website?
How can I contact Acorda Therapeutics?
Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300.
MarketBeat Community Rating for Acorda Therapeutics (NASDAQ ACOR)
MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote "Outperform" if you believe ACOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
